Country: Malaysia
Language: English
Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
INACTIVATED POLIOMYELITIS VIRUS,TYPE 3; INACTIVATED POLIOMYELITIS VIRUS,TYPE 2; INACTIVATED POLIOMYELITIS VIRUS,TYPE 1
SANOFI-AVENTIS (MALAYSIA) SDN. BHD.
INACTIVATED POLIOMYELITIS VIRUS,TYPE 3; INACTIVATED POLIOMYELITIS VIRUS,TYPE 2; INACTIVATED POLIOMYELITIS VIRUS,TYPE 1
0.5ml mL; 0.5 ml mL
SANOFI PASTEUR
NONE Read the complete document
MY/IMO/0223/SPC0722 1 N AME OF THE MEDICINAL PRODUCT IMOVAX POLIO, SUSPENSION FOR INJECTION IN PREFILLED SYRINGE POLIOMYELITIS VACCINE (INACTIVATED) 2 Q UALITATIVE AND QUANTITATIVE COMPOSITION One dose (0.5 mL) contains: Poliomyelitis virus (inactivated) Type 1 (Mahoney strain)# …. ......................................................... 40 DU *† Type 2 (MEF-1 strain)# …………………………………………..... 8 DU *† Type 3 (Saukett strain)# ……………………………………….….. 32 DU *† This vaccine complies with European Pharmacopoeia requirements and WHO recommendations. #produced on VERO cells * DU: D-antigen unit † or equivalent antigenic quantity determined by a suitable immunochemical method. IMOVAX POLIO may contain traces of neomycin, streptomycin and polymycin B (see section 4.3). Excipients with known effect: Phenylalanine…………………………………………………………………….12.5 micrograms Ethanol……………………………………………………….………………………2 milligrams For the full list of excipients, see section 6.1 3 P HARMACEUTICAL FORM Suspension for injection in prefilled syringe. IMOVAX POLIO is a clear and colourless suspension. MY/IMO/0223/SPC0722 4 C LINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination. IMOVAX POLIO must be used according to effective official recommendations. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _PEDIATRIC POPULATION _ _Primary vaccination _ One dose at the age of 2 and 4 months. _Booster _ One dose at the age of 11 months. From 6 weeks of age, IMOVAX POLIO may be administered following the 6-, 10-, 14-week schedule, as per the recommendations of the Expanded Programme on Immunization of the World Health Organisation. _ADULT POPULATION _ _Primary vaccination _ 2 doses of 0.5 ml at an interval of two months. _Booster: _ First booster: 8 to 12 months after Read the complete document